Notably, SGLT2 inhibitors can reduce hospitalization for heart failure and delay the progression of renal disease, regardless of existing atherosclerotic cardiovascular disease or heart failure history (Fitchett et al., 2016; Neal et al., 2017; Wiviott et al., 2019; Zelniker et al., 2019). Here, SLC5A2 is linked to kidney disorder.